Morepen Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Morepen Laboratories Ltd reported a 3.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 6.0%.
• Its expenses for the quarter were down by 4.3% QoQ and 0.1% YoY.
• The net profit increased 281.8% QoQ and increased 17.8% YoY.
• The earnings per share (EPS) of Morepen Laboratories Ltd stood at 0.75 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Morepen Laboratories Ltd is a renowned pharmaceutical company that has established its presence in the healthcare sector. The company primarily focuses on the manufacture and sale of pharmaceuticals, including bulk drugs, formulations, and home diagnostics. Morepen Laboratories is known for its competitive product range in both domestic and international markets. Recent developments for Morepen Laboratories might include strategic expansions, collaborations, or regulatory approvals, although specific details are not provided. The company operates in a highly competitive and regulated industry that demands continuous innovation and adherence to stringent quality standards.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Morepen Laboratories reported a total income of ₹416.21 crores. This represents a quarter-over-quarter (QoQ) decline of 3.1% compared to ₹429.65 crores in the first quarter of fiscal year 2026 (Q1FY26). Year-over-year (YoY), there was a decrease of 6.0% from ₹442.71 crores in Q2FY25. The decline in total income on both a sequential and annual basis may reflect various market conditions, operational factors, or changes in product demand.

Profitability

The company’s Profit Before Tax (PBT) for Q2FY26 was ₹45.69 crores, which shows a substantial QoQ increase of 194.4% from ₹15.52 crores in Q1FY26, though it experienced a slight YoY decrease of 0.7% compared to ₹46.02 crores in Q2FY25. Additionally, the Profit After Tax (PAT) for Q2FY26 was ₹41.04 crores, marking a significant QoQ growth of 281.8% over Q1FY26’s ₹10.75 crores and a YoY increase of 17.8% from ₹34.85 crores in Q2FY25. Earnings Per Share (EPS) followed a similar trend, standing at ₹0.75 in Q2FY26 compared to ₹0.20 in Q1FY26 and ₹0.65 in Q2FY25. These figures highlight the company's improved profitability in the latest quarter.

Operating Metrics

Total expenses in Q2FY26 were reported at ₹396.34 crores, which is a decline of 4.3% QoQ from ₹414.14 crores in Q1FY26 and a marginal decrease of 0.1% YoY from ₹396.70 crores in Q2FY25. The Tax for Q2FY26 was ₹4.65 crores, increasing 13.1% QoQ from ₹4.11 crores in Q1FY26, but experiencing a YoY decrease of 58.4% from ₹11.17 crores in Q2FY25. The financial data indicates changes in operational costs and tax implications that are critical to the company’s financial health. The variations in tax expenses could be attributed to different tax regimes or adjustments in fiscal policies affecting the company.